Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04816643
Recruitment Status : Recruiting
First Posted : March 25, 2021
Last Update Posted : November 11, 2021
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
BioNTech SE

Tracking Information
First Submitted Date  ICMJE March 19, 2021
First Posted Date  ICMJE March 25, 2021
Last Update Posted Date November 11, 2021
Actual Study Start Date  ICMJE March 24, 2021
Estimated Primary Completion Date July 23, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 29, 2021)
  • Percentage of participants in Phase 1 reporting local reactions [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    Pain or tenderness at the injection site, redness and swelling as reported on electronic diaries.
  • Percentage of participants in Phase 1 reporting systemic events [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened join pain, decreased appetite drowsiness, and irritability as reported on electronic diaries
  • Percentage of participants in Phase 1 reporting adverse events [ Time Frame: from Dose 1 through 1 month after the last dose ]
    As elicited by investigational site staff
  • Percentage of participants in Phase 1 reporting serious adverse events [ Time Frame: from Dose 1 through 6 months after the last dose ]
    As elicited by investigational site staff
  • Percentage of participants in Phase 2/3 reporting local reaction [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    Pain or tenderness at the injection site, redness and swelling as reported on electronic diaries.
  • Percentage of participants in Phase 2/3 reporting systemic events [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain, decreased appetite, drowsiness, and irritability as reported on electronic diaries
  • Percentage of participants in Phase 2/3 reporting adverse events [ Time Frame: from Dose 1 through 1 month after the last dose ]
    As elicited by investigational site staff
  • Percentage of participants in Phase 2/3 reporting serious adverse events [ Time Frame: from Dose 1 through 6 months after the last dose ]
    As elicited by investigational site staff
  • Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to <12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥5 to <12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
Original Primary Outcome Measures  ICMJE
 (submitted: March 24, 2021)
  • Percentage of participants in Phase 1 reporting local reaction in each dose level in each age group [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    For participants in ≥5 to <12 years and ≥2 to <5 years of age: Pain at the injection site, redness and swelling as reported on electronic diaries. For participants in ≥6 months to <2 years of age: Tenderness at the injection site, redness, and swelling as reported on electronic diaries
  • Percentage of participants in Phase 1 reporting systemic events in each dose level in each age group [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    For participants ≥5 to <12 years and ≥2 to <5 years of age Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened join pain as reported on electronic diaries For Participants ≥6 months to <2 years of age Fever, decreased appetite drowsiness, and irritability as reported on electronic diaries
  • Percentage of participants in Phase 1 reporting adverse events in each dose level in each age group [ Time Frame: from Dose 1 through 1 month after the last dose ]
    As elicited by investigational site staff
  • Percentage of participants in Phase 1 reporting serious adverse events in each dose level in each age group [ Time Frame: from Dose 1 through 6 months after the last dose ]
    As elicited by investigational site staff
  • Percentage of participants in Phase 2/3 reporting local reaction in each dose level in each age group [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    For participants in ≥5 to <12 years and ≥2 to <5 years of age: Pain at the injection site, redness and swelling as reported on electronic diaries. For participants in ≥6 months to <2 years of age: Tenderness at the injection site, redness, and swelling as reported on electronic diaries
  • Percentage of participants in Phase 2/3 reporting systemic events in each dose level in each age group [ Time Frame: for 7 days after Dose 1 and Dose 2 ]
    For participants in ≥5 to <12 years and ≥2 to <5 years of age: fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as reported on electronic diaries. For participants in ≥6 months to <2 years of age: Fever, decreased appetite, drowsiness, and irritability as reported on electronic diaries
  • Percentage of participants in Phase 2/3 reporting adverse events in each dose level in each age group [ Time Frame: from Dose 1 through 1 month after the last dose ]
    As elicited by investigational site staff
  • Percentage of participants in Phase 2/3 reporting serious adverse events in each dose level in each age group [ Time Frame: from Dose 1 through 6 months after the last dose ]
    As elicited by investigational site staff
  • In Phase 2/3 participants, Geometric Mean Ratio of SARS-CoV-2 neutralizing titers in participants in each age group at selected dose level to those 16 to 25 years of age in study C4591001 [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 29, 2021)
  • In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs [ Time Frame: Through 7 days after Dose 2 ]
    As measured at the central laboratory
  • In evaluable Phase 2/3 participants at selected dose level in each age group, Geometric Mean Titers of SARS-CoV-2 neutralizing titers with no serological or virological evidence of past SARS-CoV-2 infection [ Time Frame: At baseline (before Dose 1) and 1, 6, 12 (for the original BNT162b2 group only), and 24 (for the original BNT162b2 group only) months after Dose 2 ]
    As measured at the central laboratory
  • In evaluable Phase 2/3 participants at the dose level selected in each age group, Geometric Mean Fold Ratio in SARS-CoV-2 serum neutralizing titer from before vaccination to each subsequent time point [ Time Frame: From before Dose 1 to each subsequent time point after Dose 2 ]
    As measured at the central laboratory
  • In the evaluable Phase 2/3 selected-dose participants, Ratio of incidence of asymptomatic SARS-CoV-2 infection based on N-binding antibody seroconversion for the active vaccine group to the placebo group without evidence of past SARS-CoV-2 infection [ Time Frame: Through 6 months after the second dose ]
    As measured at the central laboratory
  • Ph 2/3 LDE participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to <12 years of age to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years of age in the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • Ph 2/3 LDE participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants 12 to <16 years of age to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years of age in the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • Ph 2/3 LDE participants, immunobridging of SARS-CoV-2 serum neutralizing titers in participants 16 to <30 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 55 years from Phase 2/3 of the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • In Phase 2/3 lower-dose evaluation participants, the difference in percentages of participants with seroresponse in participants ≥5 to <12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • In Phase 2/3 lower-dose evaluation participants, the difference in percentages of participants with seroresponse in participants 12 to <16 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • In lower-dose evaluation participants, the difference in percentages of participants with seroresponse in participants 16 to <30 years of age and participants 16 to 55 years of age from C4591001 study [ Time Frame: 1 month after the second dose ]
    As measured at the central laboratory
  • Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥5 to <12 years of age with successful immunobridging, without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: From 7 days after the second dose ]
    Per 1000 person-years of follow-up
  • Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥6 months to <2 years and ≥2 to <5 years of age with successful immunobridging, without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: From 7 days after the second dose ]
    Per 1000 person-years of follow-up
  • Ratio of confirmed COVID-19 illness, Ph 2/3 selected-dose in all age groups (with successful immunobridging) and if did not accrue required cases, without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: From 7 days after the second dose ]
    Per 1000 person-years of follow-up
  • Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥5 to <12 years of age with successful immunobridging, with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: From 7 days after the second dose ]
    Per 1000 person-years of follow-up
  • Ratio of confirmed COVID-19, Ph 2/3 selected-dose participants ≥6 months to <2 years and ≥2 to <5 years of age with successful immunobridging, with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: From 7 days after the second dose ]
    Per 1000 person-years of follow-up
  • Ratio of confirmed COVID-19 illness, Ph 2/3 selected-dose in all age groups (with successful immunobridging) and if did not accrue required cases, with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: From 7 days after the second dose ]
    Per 1000 person-years of follow-up
Original Secondary Outcome Measures  ICMJE
 (submitted: March 24, 2021)
  • In Phase 1 participants in each age group at each dose level, Geometric Mean Titers of SARS-CoV-2 serum neutralizing antibody titers [ Time Frame: Through 7 days after Dose 2 ]
    As measured at the central laboratory
  • In Phase 1 participants in each age group at each dose level, Geometric Mean Fold Ratio in SARS-CoV-2 serum neutralizing antibody titers from before vaccination to each subsequent time point [ Time Frame: Up to 7 days after Dose 2 ]
    As measured at the central laboratory
  • In evaluable Phase 2/3 participants at selected dose level in each age group, Geometric Mean Titers of SARS-CoV-2 neutralizing titers with no serological or virological evidence of past SARS-CoV-2 infection [ Time Frame: At baseline, and at 1, 6, 12(participants who originally received BNT162b2) and 24 months(participants who originally received BNT162b2) after dose 2 ]
    As measured at the central laboratory
  • In evaluable Phase 2/3 participants at selected dose level in each age group, Geometric Mean Fold Ratio in SARS-CoV-2 serum neutralizing titer from before vaccination to each subsequent time point [ Time Frame: from before Dose 1 and at 1, 6, 12(participants who originally received BNT162b2) and 24 months(participants who originally received BNT162b2) after dose 2 ]
    As measured at the central laboratory
  • Ratio of confirmed COVID-19 illness, in all age groups of Phase 2/3 participants without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: from 7 days after the second dose ]
    Per 1001 person-years of follow-up if at least 22 cases are accrued across the age group
  • Ratio of confirmed COVID-19 illness, in all age groups of Phase 2/3 participants with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group [ Time Frame: from 7 days after the second dose ]
    Per 1001 person-years of follow-up if at least 22 cases are accrued across the age group
  • In the evaluable Phase 2/3 participants, Ratio of incidence of asymptomatic SARS-CoV-2 infection based on N-binding antibody seroconversion for the active vaccine group to the placebo group without evidence of past SARS-CoV-2 infection [ Time Frame: Through 6 months after the second dose ]
    As measured at the central laboratory
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults
Official Title  ICMJE PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN AND YOUNG ADULTS
Brief Summary

This is a Phase 1/2/3 study in healthy children and young adults.

Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.

Detailed Description

Phase 1 Dose-Finding

Is the open-label dose-finding portion of the study that will evaluate safety, tolerability, and immunogenicity of BNT162b2 administered on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age).

Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the C4591001 study.

The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.

Dependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose.

Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess for immunogenicity to determine the final BNT162b2 dose level for the Phase 2/3.

Phase 1 Lower-Dose Evaluation

Is the open-label lower-dose evaluation portion of the study that will evaluate safety, tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, 12 to <16 years, and 16 to <30 years of age).

The purpose of the Phase 1 lower-dose evaluation is to evaluate safety and immunogenicity of BNT162b2 from up to 2 different dose levels in each age group.

Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess immunogenicity to determine the selected BNT162b2 dose level for the Phase 2/3 lower-dose evaluation portion of the study.

Phase 2/3 Selected-Dose

Is the portion of the study that will evaluate the safety, tolerability, and immunogenicity of the selected dose level in each age group at the selected dose level from Phase 1 dose finding, with a total of approximately 6750 participants as an additional 2250 participants will be included to enlarge the size of the pediatric safety database. Participants will be randomized in a 2:1 ratio to receive active vaccine or placebo.

Approximately 450 participants (300 in the active vaccine group and 150 in the placebo group) randomized in each age group in this phase will contribute to the immunobridging analysis at 1 month after Dose 2 and will contribute to the overall analysis of the persistence of immune response at 6 months after Dose 2. These participants will be enrolled from both US and EU sites to ensure this subset is representative of the whole study.

For the persistence time points of 12 and 24 months after Dose 2, approximately 70 participants from each age group in the original BNT162b2 group will have an immunogenicity blood draw in order to contribute to the analysis. All approximately 6750 participants will contribute to the VE analysis for conditional VE and asymptomatic infection. Efficacy will be evaluated within or across age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases in those age groups.

At designated US sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately 60 participants ≥10 years of age. These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points.

Phase 2/3 Lower-Dose Evaluation

Is the open-label portion of the study that will evaluate the safety, tolerability, and immunogenicity of the selected dose level in each age group from the Phase 1 lower-dose evaluation, with a total of approximately 900 active participants.

Approximately 300 active participants in each age group in this phase will contribute to the immunobridging analysis at 1 month after Dose 2 and the overall analysis of the persistence of immune response at 6 months after Dose 2. These participants will be enrolled from both US and EU sites to ensure this subset is representative of the whole study.

Phase 2/3 Obtaining Serum Samples for Potential Troponin I Testing

If testing of troponin I levels in individuals who did not receive BNT162b2 indicates that troponin I level could be a reliable indicator of potential subclinical myocarditis, obtaining serum samples for potential troponin I testing during the period of increased risk of clinical myocarditis may help characterize the absence/presence and frequency of subclinical myocarditis. To assess, an additional group of participants will be included: 5 to <12 years: 750 participants randomized 2:1 to receive BNT162b2 10 µg or placebo, and 500 participants 12 to <16 years of age: open-label receipt of BNT162b2 30 µg.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE SARS-CoV-2 Infection, COVID-19
Intervention  ICMJE
  • Biological: Biological/Vaccine: BNT162b2 10mcg
    BNT162b2 Low/Mid-Dose (10mcg) level
  • Biological: BNT162b2 20mcg
    BNT162b2 Mid-Dose (20mcg) level
  • Biological: BNT162b2 30mcg
    BNT162b2 High-Dose (30mcg) level
  • Other: Placebo
    Intramuscular injection
  • Biological: Biological/Vaccine: BNT162b2 3mcg
    BNT162b2 Low-Dose (3mcg) level
Study Arms  ICMJE
  • Experimental: Low/Mid-Dose, ≥5 to <12 Years
    Low/Mid-Dose (10mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 10mcg
  • Experimental: Mid-Dose, ≥5 to <12 Years
    Mid-Dose, (20mcg), 2 doses 21 days apart
    Intervention: Biological: BNT162b2 20mcg
  • Experimental: High-Dose, ≥5 to <12 Years
    High-Dose (30mcg), 2 doses 21 days apart
    Intervention: Biological: BNT162b2 30mcg
  • Experimental: Low/Mid-Dose, ≥2 to < 5 Years
    Low/Mid-Dose (10mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 10mcg
  • Experimental: Mid-Dose, ≥2 to <5 Years
    Mid-Dose, (20mcg), 2 doses 21 days apart
    Intervention: Biological: BNT162b2 20mcg
  • Experimental: High-Dose, ≥2 to <5 Years
    High-Dose, (30mcg), 2 doses 21 days apart
    Intervention: Biological: BNT162b2 30mcg
  • Experimental: Low/Mid-Dose, ≥6 Months to <2 Years
    Low/Mid-Dose, (10mcg), doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 10mcg
  • Experimental: Mid-Dose, ≥6 Months to <2 Years
    Mid-Dose, (20mcg), doses 21 days apart
    Intervention: Biological: BNT162b2 20mcg
  • Experimental: High-Dose, ≥6 Months to <2 Years
    High-Dose, (30mcg), 2 doses 21 days apart
    Intervention: Biological: BNT162b2 30mcg
  • Experimental: Low-Dose, ≥5 to <12 Years
    Low-Dose (3mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 3mcg
  • Experimental: Low-Dose, 16 to <30 Years
    Low-Dose (3mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 3mcg
  • Experimental: Low/Mid-Dose, 16 to <30 Years
    Low/Mid-Dose (10mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 10mcg
  • Placebo Comparator: Placebo, ≥6 Months to <2 Years
    Intervention: Other: Placebo
  • Placebo Comparator: Placebo, ≥2 to <5 Years
    Intervention: Other: Placebo
  • Placebo Comparator: Placebo, ≥5 to <12 Years
    Intervention: Other: Placebo
  • Experimental: Low-Dose, ≥6 Months to <2 Years
    Low-Dose (3mcg), 2 doses 21 doses apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 3mcg
  • Experimental: Low-Dose, ≥2 to <5 Years
    Low-Dose (3mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 3mcg
  • Experimental: Low-dose, 12 to <16 Years
    Low-Dose (3mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 3mcg
  • Experimental: Low/Mid-Dose, 12 to <16 Years
    Low/Mid-Dose (10mcg), 2 doses 21 days apart
    Intervention: Biological: Biological/Vaccine: BNT162b2 10mcg
  • Experimental: High-Dose, 12 to <16 Years
    High-Dose (30mcg), 2 doses 21 days apart
    Intervention: Biological: BNT162b2 30mcg
  • Experimental: Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)
    Low/Mid-Dose (10mcg), 2 doses 21 days apart. A separate cohort of participants to collect serum samples for potential troponin I testing
    Intervention: Biological: Biological/Vaccine: BNT162b2 10mcg
  • Experimental: Placebo, ≥5 to <12 Years (Troponin I Testing)
    A separate cohort of participants to collect serum samples for potential troponin I testing
    Intervention: Other: Placebo
Publications * Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simões EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Rämet M, Munjal I, Perez JL, Frenck RW Jr, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Türeci Ö, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2021 Nov 9. doi: 10.1056/NEJMoa2116298. [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 4, 2021)
11422
Original Estimated Enrollment  ICMJE
 (submitted: March 24, 2021)
4644
Estimated Study Completion Date  ICMJE July 23, 2024
Estimated Primary Completion Date July 23, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  1. Male or female participants ≥6 months to <12 years of age, at the time of randomization, at Visit 1 for the dose-finding/selected-dose evaluation and for participants ≥5 to <30 years of age, at the time of randomization, at Visit 1 for the lower-dose evaluation. For the obtaining-serum-samples-for-potential-troponin I-testing portion of the study: Male or female participants between ≥5 and <16 years of age.
  2. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  3. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.

    Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in the therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.

  4. Participants are expected to be available for the duration of the study and whose parent(s)/legal guardian can be contacted by telephone during study participation.
  5. Negative urine pregnancy test for female participants who are biologically capable of having children.
  6. Female participant of childbearing potential or male participant able to father children who is willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children.
  7. The participant or participant's parent(s)/legal guardian is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written).

Exclusion Criteria

  1. Phase 1 only: Past clinical (based on COVID-19 symptoms/signs alone, if a SARS CoV 2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.
  2. Phase 1 only: Known infection with HIV, HCV, or HBV.
  3. Receipt of medications intended to prevent COVID-19.
  4. Previous or current diagnosis of MIS-C.
  5. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Note: This includes both conditions that may increase the risk associated with study intervention administration or a condition that may interfere with the interpretation of study results
  6. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  7. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  8. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.
  9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  10. Female who is pregnant or breastfeeding.
  11. Previous vaccination with any coronavirus vaccine.
  12. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  13. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study.
  14. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  15. Previous participation in other studies involving study intervention containing LNPs.
  16. Participants who are direct descendants (child or grandchild) of investigational site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Months to 30 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com
Listed Location Countries  ICMJE Finland,   Poland,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04816643
Other Study ID Numbers  ICMJE C4591007
2020-005442-42 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Responsible Party BioNTech SE
Study Sponsor  ICMJE BioNTech SE
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account BioNTech SE
Verification Date November 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP